What's Going On With Novo Nordisk Shares Monday?

Novo Nordisk A/S NVO shares are trading higher Monday after the company announced European Union approval for oral semaglutide to reduce cardiovascular death, heart attack and stroke.

What To Know: : The European Medicines Agency's Committee for Medicinal Products for Human Use approved an update to the Rybelsus (oral semaglutide) label to reflect cardiovascular benefits demonstrated in the SOUL trial. The phase 3b study showed Rybelsus reduced the risk of major adverse cardiovascular events — a composite of cardiovascular death, heart attack and stroke — by 14% versus placebo in adults with type 2 diabetes at high cardiovascular risk.

The company said new SOUL results will also be presented this week at the European Association for the Study of Diabetes annual meeting, highlighting reduced hospitalizations and consistent cardiovascular benefits across body weight categories.

How To Buy Novo Nordisk Shares

By now you're likely curious about how to participate in the market for Novo Nordisk NVO – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

See Also: Inside Helius Medical’s $500 Million Raise — And Its Solana Treasury Plans

NVO Price Action: At the time of writing, Novo Nordisk shares are trading 1.90% higher at $55.91, according to data from Benzinga Pro.

Image via Shutterstock